NCBiotech : Spotlight : Novartis

At Novartis Gene Therapies, the company's goal is to develop and commercialize gene therapies for patients and families affected by rare and life-threatening neurological genetic diseases. Already, its initial gene therapy for spinal muscular atrophy has been approved in the U.S., Japan, the European Union, Israel, Brazil and Canada. (Photo Courtesy of Novartis)